glp-1 next generation The of weight loss drugs Introducing the new GLP-1 Complete,

Dulaglutide, semaglutide, tirzepatide: potential for altered medicinal product exposure (Tmax, Cmax) when administered with oral medicinal products with rapid gastrointestinal absorption or prolonged release, due to delayed gastric emptying

(Source 3) 6

In a six-week randomized controlled trial on 24 diabetic participants, supplementation with 500 mg of hesperidin per day improved glycemic control, increased total antioxidant capacity, and reduced oxidative stress and DNA injury (Homayouni 2017)

Current research suggests that peptide therapies may be well tolerated when prescribed appropriately and monitored by qualified healthcare professionals